Aerie Pharmaceuticals Announces Public Offering of Common Stock
May 25 2017 - 4:02PM
Business Wire
Aerie Pharmaceuticals, Inc. (NASDAQ:AERI), a clinical-stage
pharmaceutical company focused on the discovery, development and
commercialization of first-in-class therapies for the treatment of
patients with glaucoma and other diseases of the eye, today
announced that it has commenced a registered underwritten public
offering of $50 million of shares of its common stock.
Cantor Fitzgerald & Co. is acting as the sole bookrunner for
the offering.
Aerie intends to use the net proceeds of the offering for
general corporate purposes, including to fund expansion of its
commercialization programs in North America for both RhopressaTM
and RoclatanTM, its potential preclinical and clinical activities
for pipeline therapy and delivery technology opportunities, its
clinical and commercialization efforts beyond North America, and
its manufacturing activities, including the construction of its
manufacturing plant and the addition of secondary contract
manufacturers, for working capital and potentially for the
expansion of its external business development programs.
A shelf registration statement relating to the shares is
effective with the Securities and Exchange Commission. The shares
may be offered only by means of the prospectus forming a part of
the effective registration statement and a related prospectus
supplement. A preliminary prospectus supplement related to the
offering will be filed with the Securities and Exchange Commission
today. An electronic copy of the preliminary prospectus supplement
and the accompanying prospectus will be available on the website of
the Securities and Exchange Commission at www.sec.gov. Copies of
the preliminary prospectus supplement and the final prospectus
supplement, when available, and the accompanying prospectus may be
obtained by contacting Cantor Fitzgerald & Co., Attn: Capital
Markets, 499 Park Ave., 5th Floor, New York, New York 10022, or by
telephone at 212-829-7122, or by e-mail at
prospectus@cantor.com.
This press release does not constitute an offer to sell or the
solicitation of an offer to buy any securities of Aerie, and shall
not constitute an offer, solicitation or sale of any security in
any state or jurisdiction in which such offer, solicitation or sale
would be unlawful prior to registration or qualification under the
securities laws of any such state or jurisdiction.
About Aerie Pharmaceuticals, Inc.
Aerie is a clinical-stage pharmaceutical company focused on the
discovery, development and commercialization of first-in-class
therapies for the treatment of patients with glaucoma and other
diseases of the eye. Aerie’s two current product candidates are
once-daily intraocular pressure-lowering therapies with novel
mechanisms of action to treat patients with glaucoma or ocular
hypertension. The NDA (new drug application) for RhopressaTM
(netarsudil ophthalmic solution) 0.02% was submitted to the U.S.
Food and Drug Administration (FDA) in February 2017, and, in May
2017, the FDA set the PDUFA (Prescription Drug User Fee Act) goal
date for the completion of the FDA’s review of the RhopressaTM NDA
for February 28, 2018. Aerie’s second product candidate, RoclatanTM
(netarsudil/latanoprost ophthalmic solution) 0.02%/0.005%, which is
a fixed dose combination of RhopressaTM and widely prescribed PGA
latanoprost, achieved its primary efficacy endpoint in two Phase 3
registration trials, named Mercury 1, which is still ongoing, and
Mercury 2. A RoclatanTM NDA submission is expected to take place in
the first half of 2018. Aerie is also focused on the development of
additional product candidates and technologies in
ophthalmology.
Forward-Looking Statements
This press release contains forward-looking statements for
purposes of the safe harbor provisions of the Private Securities
Litigation Reform Act of 1995. We may, in some cases, use terms
such as “predicts,” “believes,” “potential,” “proposed,”
“continue,” “estimates,” “anticipates,” “expects,” “plans,”
“intends,” “may,” “could,” “might,” “will,” “should,” “exploring,”
“pursuing” or other words that convey uncertainty of future events
or outcomes to identify these forward-looking statements.
Forward-looking statements include statements regarding our
intentions, beliefs, projections, outlook, analyses or current
expectations concerning, among other things: the success, timing
and cost of our ongoing and anticipated preclinical studies and
clinical trials for our current and potential future product
candidates, including statements regarding the timing of initiation
and completion of the studies and trials; our expectations
regarding the clinical effectiveness of our product candidates and
results of our clinical trials; the timing of and our ability to
request, obtain and maintain FDA or other regulatory authority
approval of, or other action with respect to, our product
candidates, including the expected timing of, and timing of
regulatory and/or other review of, filings for our product
candidates; our expectations regarding the commercialization and
manufacturing of our product candidates; our expectations related
to the offering discussed in this press release, including the
completion, timing and size of the offering and the use of proceeds
therefrom; the potential advantages of our product candidates; our
plans to pursue development of additional product candidates and
technologies in ophthalmology, including development of our product
candidates for additional indications and other therapeutic
opportunities; our plans to explore possible uses of our existing
proprietary compounds beyond glaucoma; our ability to protect our
proprietary technology and enforce our intellectual property
rights; and our expectations regarding strategic operations,
including our ability to in-license or acquire additional
ophthalmic products or product candidates or technologies. By their
nature, forward-looking statements involve risks and uncertainties
because they relate to events, competitive dynamics, industry
change and other factors beyond our control, and depend on
regulatory approvals and economic and other environmental
circumstances that may or may not occur in the future or may occur
on longer or shorter timelines than anticipated. We discuss many of
these risks in greater detail under the heading “Risk Factors” in
the quarterly and annual reports that we file with the Securities
and Exchange Commission (SEC). In particular, the receipt of the
PDUFA goal date notification does not constitute FDA approval of
the RhopressaTM NDA, and there can be no assurance that the FDA
will complete its review by the PDUFA goal date, that the FDA will
not require changes or additional data, whether as a result of
recommendations, if any, made by any FDA advisory committee or
otherwise, that must be made or received before it will approve the
NDA, if ever, or that the FDA will approve the NDA. Forward-looking
statements are not guarantees of future performance and our actual
results of operations, financial condition and liquidity, and the
development of the industry in which we operate may differ
materially from the forward-looking statements contained in this
press release. Any forward-looking statements that we make in this
press release speak only as of the date of this press release. We
assume no obligation to update our forward-looking statements
whether as a result of new information, future events or otherwise,
after the date of this press release.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20170525006030/en/
Aerie PharmaceuticalsRichard Rubino,
908-947-3540rrubino@aeriepharma.comorBurns McClellan, Inc., on
behalf of Aerie PharmaceuticalsInvestorsAmi Bavishi,
212-213-0006abavishi@burnsmc.comorMediaJustin Jackson,
212-213-0006jjackson@burnsmc.com
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Aug 2024 to Sep 2024
Aerie Pharmaceuticals (NASDAQ:AERI)
Historical Stock Chart
From Sep 2023 to Sep 2024